Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03288532
Title Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors University College, London
Indications

renal cell carcinoma

Therapies

Durvalumab

Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.